KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium

Reuters11-18

KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium

KORU Medical Systems Inc. has announced the upcoming presentation of research findings on its FreedomEDGE® Syringe Infusion System at the ESID/EHA/SIOPE Focused Symposium 2025, scheduled to take place in Vienna, Austria, from November 18-20, 2025. The multicenter study compared the FreedomEDGE® Infusion System with traditional manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings. The evaluation, conducted across nine hospitals in Denmark, assessed nurse satisfaction, patient experience, usability, and workflow efficiency. Key findings included high nurse satisfaction, with 91% reporting the system was easier to use and had faster setup times, as well as high patient satisfaction, with 73% noting improved comfort. KORU Medical plans to submit a 510(k) filing to the FDA for use of the device with a commercialized oncology drug in late 2025 or early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117987769) on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584671711?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584671711","market":"fut","top_or_hot":-1,"title":"KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KORU Medical Systems Inc. has announced the upcoming presentation of research findings on its FreedomEDGE® Syringe Infusion System at the ESID/EHA/SIOPE Focused Symposium 2025, scheduled to take place in Vienna, Austria, from November 18-20, 2025. The multicenter study compared the FreedomEDGE® Infusion System with traditional manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings. The evaluation, conducted across nine hospitals in Denmark, assessed nurse satisfaction, patient experience, usability, and workflow efficiency. Key findings included high nurse satisfaction, with 91% reporting the system was easier to use and had faster setup times, as well as high patient satisfaction, with 73% noting improved comfort. KORU Medical plans to submit a 510(k) filing to the FDA for use of the device with a commercialized oncology drug in late 2025 or early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117987769) on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KORU Medical Systems Inc. has announced the upcoming presentation of research findings on its FreedomEDGE® Syringe Infusion System at the ESID/EHA/SIOPE Focused Symposium 2025, scheduled to take place in Vienna, Austria, from November 18-20, 2025. The multicenter study compared the FreedomEDGE® Infusion System with traditional manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings. The evaluation, conducted across nine hospitals in Denmark, assessed nurse satisfaction, patient experience, usability, and workflow efficiency. Key findings included high nurse satisfaction, with 91% reporting the system was easier to use and had faster setup times, as well as high patient satisfaction, with 73% noting improved comfort. KORU Medical plans to submit a 510(k) filing to the FDA for use of the device with a commercialized oncology drug in late 2025 or early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117987769) on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRMD","symbol_name":"Repro Med Systems, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL9j4bHv:1","article_id":"2584671711","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584671711","pubTimestamp":1763413544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"KORU Medical Systems Inc. has announced the upcoming presentation of research findings on its FreedomEDGE Syringe Infusion System at the ESID/EHA/SIOPE Focused Symposium 2025, scheduled to take place in Vienna, Austria, from November 18-20, 2025. The multicenter study compared the FreedomEDGE Infusion System with traditional manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings. The evaluation, conducted across nine hospitals in Denmark, assessed nurse satisfaction, patient experience, usability, and workflow efficiency. Key findings included high nurse satisfaction, with 91% reporting the system was easier to use and had faster setup times, as well as high patient satisfaction, with 73% noting improved comfort. KORU Medical plans to submit a 510 filing to the FDA for use of the device with a commercialized oncology drug in late 2025 or early 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRMD":"Repro Med Systems, Inc.","BK4082":"医疗保健设备"},"translate_title":"KORU Medical在2025年研讨会上公布FreedomEDGE输液系统的积极研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRMD":0.9},"content_text":"KORU Medical Unveils Positive Study Results for FreedomEDGE Infusion System at 2025 Symposium\n    \n\n        KORU Medical Systems Inc. has announced the upcoming presentation of research findings on its FreedomEDGE® Syringe Infusion System at the ESID/EHA/SIOPE Focused Symposium 2025, scheduled to take place in Vienna, Austria, from November 18-20, 2025. The multicenter study compared the FreedomEDGE® Infusion System with traditional manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings. The evaluation, conducted across nine hospitals in Denmark, assessed nurse satisfaction, patient experience, usability, and workflow efficiency. Key findings included high nurse satisfaction, with 91% reporting the system was easier to use and had faster setup times, as well as high patient satisfaction, with 73% noting improved comfort. KORU Medical plans to submit a 510(k) filing to the FDA for use of the device with a commercialized oncology drug in late 2025 or early 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117987769) on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584671711","isCrawlerRequest":true}